Current Use in Intensive Care Units by Intensivists of Antihypertensive Drugs

• Conditions: Antihypertensive Drugs in ICU

• Registration Number: NCT04924946
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Multicenter, prospective and observational study of practices and impacts of the use of antihypertensive therapies in intensive medicine and intensive care

Detailed Description

Multicenter, prospective observational cohort study on 200 patients, by doctor's questionnaire on the prescription of antihypertensive drugs in intensive care, follow-up over 72 hours of the prescription.

Study Timeline

• Study Start: 2019-06-01
• Primary Completion: 2019-06-01
• Status Verified: 2021-04
• Study First Submitted: 2021-04-29
• Study First Submitted QC: 2021-06-07
• Last Update Submitted: 2021-06-07
• Study First Posted: 2021-06-14
• Last Update Posted: 2021-06-14
• Study Completion: 2021-08-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Adult patient
• Admitted to an intensive care unit
• Patient having presented a state of circulatory shock, defined by the need for continuous administration of a vasopressive amine for at least one hour, among: Noradrenaline, Adrenaline
• In whom the introduction of drug treatment for antihypertensive purposes is decided

Exclusion Criteria

• Patient admitted to intensive care for a hypertensive emergency (hypertensive surge or malignant arterial hypertension leading to organ dysfunction
• Patient who has already received at least one anti-hypertensive drug during his stay in intensive care
• Cerebro-injured patient, proven or suspected cerebral edema, head trauma <1 month, decrease in cerebral perfusion measured
• Proven or suspected active bleeding
• Patient refusal of participation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings	60 days after inclusion	reasons for prescribers

Secondary Outcome Measures

Name	Time	Method
Search for efficiency differences between the different molecules	60 days after inclusion	Improved kidney function
Search for differences in side effects between the different molecules	60 days after inclusion	Other side effect

Trial Locations

Locations (7)

Intensive Care Victor Dupouy Hospital; 🇫🇷 Argenteuil, France

Intensive Care René Dubos Hospital; 🇫🇷 Pontoise, France

Intensive Care Bichat Hospital; 🇫🇷 Paris, France

Intensive Care Avicenne Hsopital; 🇫🇷 Bobigny, France

Intensive Care Tours Hospital; 🇫🇷 Tours, France

Intensive Care Longjumeau Hospital; 🇫🇷 Longjumeau, France

Intensive Care Louis Mourier Hospital; 🇫🇷 Colombes, France